PMID- 29358310
OWN - NLM
STAT- MEDLINE
DCOM- 20180815
LR  - 20181113
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Feb 28
TI  - 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer 
      compound.
LID - BSR20171440 [pii]
LID - 10.1042/BSR20171440 [doi]
AB  - The 7-nitro-2,1,3-nitrobenzoxadiazole (NBD) derivatives are a series of compounds 
      containing the NBD scaffold that are not glutathione (GSH) peptidomimetics, and 
      result in a strong inhibition of glutathione S-transferases (GSTs). Growing 
      evidences highlight their pivotal roles and outstanding anticancer activity in 
      different tumor models. In particular, 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) 
      hexanol (NBDHEX) is extensively studied, which is a very efficient inhibitor of 
      GSTP1-1. It triggers apoptosis in several tumor cell lines and this cytotoxic 
      activity is observed at micro and submicromolar concentrations. Importantly, 
      studies have shown that NBDHEX acts as an anticancer drug by inhibiting GSTs 
      catalytic activity, avoiding inconvenience of the inhibitor extrusion from the 
      cell by specific pumps and disrupting the interaction between the GSTP1-1 and key 
      signaling effectors. Additionally, some researchers also have discovered that 
      NBDHEX can act as late-phase autophagy inhibitor, which opens new opportunities 
      to fully exploit its therapeutic potential. In this review, we summarize the 
      advantages, anticancer mechanisms, and analogs of this compound, which will 
      establish the basis on the usage of NBDHEX in clinical applications in future.
CI  - (c) 2018 The Author(s).
FAU - Sha, Huan-Huan
AU  - Sha HH
AD  - The Fourth Clinical School of Nanjing Medical University and Nanjing Medical 
      University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, China.
FAU - Wang, Zhen
AU  - Wang Z
AD  - The First Clinical School of Nanjing Medical Universityand Department of 
      Orthopedics, the First Affiliated Hospital of Nanjing Medical University, 
      Guangzhou Road300, Nanjing 210009, China.
FAU - Dong, Shu-Chen
AU  - Dong SC
AD  - The Fourth Clinical School of Nanjing Medical University and Nanjing Medical 
      University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, China.
FAU - Hu, Tian-Mu
AU  - Hu TM
AD  - Department of Biological Science, Purdue University, West Lafayette, IN 47906, 
      U.S.A.
FAU - Liu, Si-Wen
AU  - Liu SW
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, 
      China.
FAU - Zhang, Jun-Ying
AU  - Zhang JY
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, 
      China.
FAU - Wu, Yang
AU  - Wu Y
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, 
      China.
FAU - Ma, Rong
AU  - Ma R
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, 
      China.
FAU - Wu, Jian-Zhong
AU  - Wu JZ
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, 
      China.
FAU - Chen, Dan
AU  - Chen D
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, 
      China.
FAU - Feng, Ji-Feng
AU  - Feng JF
AD  - Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing 
      Medical University Affiliated Cancer Hospital, Baiziting42, Nanjing 210009, China 
      jifeng_feng@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180213
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol)
RN  - 0 (7-nitrobenz-2-oxa-1,3-diazol-4-yl)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Azoles)
RN  - 0 (Hexanols)
RN  - 0 (Nitrobenzenes)
RN  - 0 (Oxadiazoles)
RN  - EC 2.5.1.18 (GSTP1 protein, human)
RN  - EC 2.5.1.18 (Glutathione S-Transferase pi)
SB  - IM
MH  - Antineoplastic Agents/*chemistry/therapeutic use
MH  - Apoptosis/drug effects
MH  - Azoles/chemistry/therapeutic use
MH  - Drug Resistance, Neoplasm/drug effects
MH  - Glutathione S-Transferase pi/*antagonists & inhibitors/chemistry
MH  - Hexanols/chemistry/therapeutic use
MH  - Humans
MH  - Neoplasms/*drug therapy/pathology
MH  - Nitrobenzenes/chemistry/therapeutic use
MH  - Oxadiazoles/*chemistry/therapeutic use
PMC - PMC5809612
OTO - NOTNLM
OT  - GSTP1-1 (Glutathione S-transferase Pi)
OT  - JNK (c-Jun N-Terminal Kinase)
OT  - NBDHEX (6- (7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol)
OT  - anticancer
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2018/01/24 06:00
MHDA- 2018/08/16 06:00
PMCR- 2018/02/13
CRDT- 2018/01/24 06:00
PHST- 2017/10/25 00:00 [received]
PHST- 2018/01/20 00:00 [revised]
PHST- 2018/01/22 00:00 [accepted]
PHST- 2018/01/24 06:00 [pubmed]
PHST- 2018/08/16 06:00 [medline]
PHST- 2018/01/24 06:00 [entrez]
PHST- 2018/02/13 00:00 [pmc-release]
AID - BSR20171440 [pii]
AID - 10.1042/BSR20171440 [doi]
PST - epublish
SO  - Biosci Rep. 2018 Feb 13;38(1):BSR20171440. doi: 10.1042/BSR20171440. Print 2018 
      Feb 28.